Your session is about to expire
← Back to Search
Local Anesthetic
Liposomal bupivacaine for Benign Tumors
Phase 4
Waitlist Available
Research Sponsored by Samaritan Health Services
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
All benign soft tissue tumors greater than one cubic cm
Adults 18 years and older
Timeline
Screening 3 weeks
Treatment Varies
Follow Up first 7 days postoperatively
Awards & highlights
Study Summary
This study is evaluating whether a drug called Exparel can improve pain and functional outcomes for patients who have had a benign soft tissue tumor resection.
Eligible Conditions
- Benign Tumors
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ first 7 days postoperatively
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~first 7 days postoperatively
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Opioid Use
Secondary outcome measures
Pain Score
Other outcome measures
Musculoskeletal Tumor Society Score (MSTS score)
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: experimentalExperimental Treatment1 Intervention
Exparel group
Group II: controlActive Control1 Intervention
plain bupivacaine
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bupivacaine
FDA approved
Find a Location
Who is running the clinical trial?
Samaritan Health ServicesLead Sponsor
3 Previous Clinical Trials
80 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger